Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1IRVINE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Ambros Therapeutics, Inc. today announced that the first patient has been dosed in its pivotal CRPS-RISE Phase 3 clinical trial evaluating neridronate versus placebo for the treatment of Complex Regional Pain Syndrome Type 1 (CRPS-1). CRPS-1 is a severe, debilitating rare disease with an estimated 65,000 new cases annually in the United States.
